日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression

剂量学分析表明,在PSMA高表达的非前列腺癌中,[¹⁷⁷Lu]Lu-PSMA-617清除迅速且吸收剂量低。

Khreish, Fadi; Rosar, Florian; Burgard, Caroline; Petto, Sven; Maus, Stephan; Stemler, Tobias; Bartholomä, Mark; Sabet, Amir; Schaefer-Schuler, Andrea; Ezziddin, Samer

Outcome and safety of single-dose docetaxel-augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience

使用[¹⁷⁷Lu]Lu-PSMA-617放射性配体进行单剂量多西他赛增强靶向放射性核素治疗治疗难治性转移性去势抵抗性前列腺癌的疗效和安全性:一项试点研究的初步证据

Ebert, Niklas; Rosar, Florian; Burgard, Caroline; Bartholomä, Mark; Maus, Stephan; Hein, Connor; Blickle, Arne; Ezziddin, Samer; Khreish, Fadi

OA20 A case of rapidly progressive interstitial lung disease in anti-Ro52 positive amyopathic dermatomyositis

OA20 一例抗Ro52阳性无肌病性皮肌炎合并快速进展性间质性肺病

Fleckenstein, Jochen; Jelden, Michael; Kremp, Stephanie; Jagoda, Philippe; Stroeder, Jonas; Khreish, Fadi; Ezziddin, Samer; Buecker, Arno; Rübe, Christian; Schneider, Guenther K; Chaudhry, Shiza; Lopez, Keimee; Raghunath, Radhikha; Ogunbambi, Olabambo

Efficacy and safety of rechallenge [(177)Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study)

在 mCRPC 患者首次部分缓解后再次使用 [(177)Lu]Lu-PSMA-617 RLT 的疗效和安全性:前瞻性注册研究的评估(REALITY 研究)

Rosar, Florian; Schuler, Joelle; Burgard, Caroline; Blickle, Arne; Bartholomä, Mark; Maus, Stephan; Petto, Sven; Khreish, Fadi; Schaefer, Andrea; Ezziddin, Samer

Analysis of Molecular Imaging Biomarkers Derived from [(18)F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [(225)Ac]Ac-PSMA-617-Augmented [(177)Lu]Lu-PSMA-617 Radioligand Therapy

对转移性去势抵抗性前列腺癌 (mCRPC) 患者 [(18)F]FDG PET/CT 衍生的分子影像生物标志物进行分析:全身总病灶糖酵解 (TLG) 可预测接受 [(225)Ac]Ac-PSMA-617 增强的 [(177)Lu]Lu-PSMA-617 放射性配体治疗患者的总生存期

Burgard, Caroline; Khreish, Fadi; Dahlmanns, Lukas; Blickle, Arne; Bastian, Moritz B; Speicher, Tilman; Maus, Stephan; Schaefer-Schuler, Andrea; Bartholomä, Mark; Petto, Sven; Ezziddin, Samer; Rosar, Florian

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

在PSMA-RLT治疗期间,采用FDG/PSMA双重PET显像预测mCRPC病灶进展。

Rosar, Florian; Burgard, Caroline; David, Scott; Marlowe, Robert J; Bartholomä, Mark; Maus, Stephan; Petto, Sven; Khreish, Fadi; Schaefer-Schuler, Andrea; Ezziddin, Samer

[(89)Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [(68)Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis

[(89)Zr]Zr-PSMA-617 PET/CT 对前列腺癌生化复发患者 [(68)Ga]Ga-PSMA-11 PET/CT 结果不确定的表征:基于病灶的分析

Rosar, Florian; Burgard, Caroline; Larsen, Elena; Khreish, Fadi; Marlowe, Robert J; Schaefer-Schuler, Andrea; Maus, Stephan; Petto, Sven; Bartholomä, Mark; Ezziddin, Samer

Outstanding increase in tumor-to-background ratio over time allows tumor localization by [(89)Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer

随着时间的推移,肿瘤与背景比值的显著增加使得[(89)Zr]Zr-PSMA-617 PET/CT能够用于前列腺癌早期生化复发时的肿瘤定位。

Burgard, Caroline; Rosar, Florian; Larsen, Elena; Khreish, Fadi; Linxweiler, Johannes; Marlowe, Robert J; Schaefer-Schuler, Andrea; Maus, Stephan; Petto, Sven; Bartholomä, Mark; Ezziddin, Samer

Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves' disease: comparison of conventional versus lithium-augmented radioiodine therapy

在格雷夫斯病中,同时使用锂可增加放射性碘的摄取量和单位给药活性下的吸收剂量:传统放射性碘疗法与锂增强放射性碘疗法的比较

Khreish, Fadi; Schaefer-Schuler, Andrea; Roth, Leonie; Burgard, Caroline; Rosar, Florian; Ezziddin, Samer

Peripapillary Atrophy Area as an Indicator of Glaucomatous Structural and Functional Progression

视乳头周围萎缩面积作为青光眼结构和功能进展的指标

Khreish, Maroun; Schuman, Joel S; Lee, TingFang; Ghassabi, Zeinab; Zambrano, Ronald; Hu, Jiyuan; Ishikawa, Hiroshi; Wollstein, Gadi; Lavinsky, Fabio